Kevin Feeley Sells 1,430 Shares of GeneDx Holdings Corp. (NASDAQ:WGS) Stock

GeneDx Holdings Corp. (NASDAQ:WGS) CFO Kevin Feeley sold 1,430 shares of the stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $76.04, for a total value of $108,737.20. Following the transaction, the chief financial officer now owns 26,770 shares of the company’s stock, valued at $2,035,590.80. The trade was a 5.07 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.

Kevin Feeley also recently made the following trade(s):

• On Monday, December 16th, Kevin Feeley sold 3,728 shares of GeneDx stock. The stock was sold at an average price of $76.75, for a total transaction of $286,124.00.
• On Monday, December 9th, Kevin Feeley sold 1,137 shares of GeneDx stock. The stock was sold at an average price of $76.37, for a total value of $86,832.69.
• On Monday, December 2nd, Kevin Feeley sold 263 shares of GeneDx stock. The stock was sold at an average price of $78.39, for a total transaction of $20,616.57.
• On Thursday, November 21st, Kevin Feeley sold 12,019 shares of GeneDx stock. The stock was sold at an average price of $73.76, for a total value of $886,521.44.
• On Tuesday, October 29th, Kevin Feeley sold 274 shares of GeneDx stock. The stock was sold at an average price of $66.60, for a total value of $18,248.40.

GeneDx Trading Up 13.2 %

Shares of WGS traded up $10.47 during midday trading on Monday, hitting $89.61. 1,259,011 shares of the stock were exchanged, compared to its average volume of 808,279. GeneDx Holdings Corp. has a 52-week low of $2.80 and a 52-week high of $89.66. The stock has a fifty day simple moving average of $76.28 and a 200 day simple moving average of $51.22. The firm has a market cap of $2.46 billion, a P/E ratio of -28.81 and a beta of 2.03. The company has a debt-to-equity ratio of 0.25, a quick ratio of 2.27 and a current ratio of 2.40.

GeneDx (NASDAQ:WGS) last issued its earnings results on Tuesday, October 29th. The company reported $0.04 earnings per share for the quarter, topping the consensus estimate of ($0.21) by $0.25. GeneDx had a negative return on equity of 13.35% and a negative net margin of 31.25%. The business had revenue of $76.90 million for the quarter, compared to analyst estimates of $64.98 million. During the same quarter last year, the company earned ($0.82) EPS. The business’s quarterly revenue was up 44.3% on a year-over-year basis. On average, research analysts anticipate that GeneDx Holdings Corp. will post -0.24 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of analysts have recently commented on the stock. Wells Fargo & Company lifted their price target on shares of GeneDx from $34.00 to $75.00 and gave the stock an “equal weight” rating in a research note on Wednesday, October 30th. The Goldman Sachs Group boosted their target price on shares of GeneDx from $54.00 to $70.00 and gave the stock a “neutral” rating in a report on Wednesday, October 30th. Finally, Craig Hallum upped their price target on shares of GeneDx from $70.00 to $95.00 and gave the company a “buy” rating in a report on Wednesday, October 30th. Three equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $59.33.

Institutional Trading of GeneDx

Institutional investors have recently made changes to their positions in the stock. Renaissance Technologies LLC acquired a new stake in shares of GeneDx in the second quarter valued at about $2,362,000. Chartwell Investment Partners LLC acquired a new position in shares of GeneDx in the 3rd quarter worth approximately $1,722,000. Charles Schwab Investment Management Inc. increased its stake in GeneDx by 304.3% during the third quarter. Charles Schwab Investment Management Inc. now owns 147,034 shares of the company’s stock valued at $6,240,000 after purchasing an additional 110,666 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC bought a new position in GeneDx in the third quarter worth about $325,000. Finally, Lisanti Capital Growth LLC bought a new stake in GeneDx in the third quarter valued at $1,554,000. 61.72% of the stock is owned by hedge funds and other institutional investors.

GeneDx Company Profile

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.